American Journal of Cardiovascular Drugs

, Volume 11, Issue 4, pp 253–263

Attenuation of Rate of Change in Carotid Intima-Media Thickness by Lipid-Modifying Drugs

Impact on Clinical Outcomes
  • Sanne A. E. Peters
  • Hester M. den Ruijter
  • Michiel L. Bots
Current Opinion


Measurements of carotid intima-media thickness (CIMT) are widely used in clinical research as a measure of atherosclerosis. Many randomized controlled trials (RCTs) have been performed using the rate of change in CIMT as the primary endpoint to study the efficacy of lipid-modifying therapies. The main advantage of using CIMT over the use of cardiovascular events as a primary endpoint is the greater efficiency and feasibility. The underlying assumption for the use of CIMT in trials is that the rate of change in CIMT achieved by a therapy reflects a change in the risk for cardiovascular events. We therefore set out to assess the evidence showing whether the rate of change in CIMT induced by lipid-lowering therapies has an impact on clinical outcomes, by reviewing the available evidence based on a search of the PubMed database. Solid evidence from observational studies shows that increased CIMT relates to an increase in cardiovascular risk. RCTs consistently demonstrate that the annual rate of change in CIMT is favourably affected by lipid-modifying therapies. One study investigating the relationship between the rate of change in CIMT and clinical events has been published and showed a positive relationship between these two outcomes. A published meta-analysis based on pooled CIMT data from statin trials has shown a positive relationship between attenuated rate of change in CIMT after statin therapy and clinical outcomes. However, methodological issues question the validity of the meta-analytical approach. The consistent agreement between results from CIMT trials and event trials on the effects of lipid-modifying therapies, however, clearly supports the presence of a relationship between changes in CIMT and clinical endpoints. Therefore, although direct evidence is scarce, the data overall on whether the attenuation of rate of change in CIMT by lipid-lowering therapies impact on clinical outcomes are supportive.


  1. 1.
    World Health Organization. The World Health Report 2008 [online]. Available from URL: http://wwwwhoint/whr/en/ [Accessed 2009 Jun 7].
  2. 2.
    Salonen R, Salonen JT. Determinants of carotid intima-media thickness: a population-based ultrasonography study in eastern Finnish men. J Intern Med 1991 Mar; 229(3): 225–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997 Sep 2; 96(5): 1432–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Dijk JM, van der GY, Bots ML, et al. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J 2006 Aug; 27(16): 1971–8.PubMedCrossRefGoogle Scholar
  5. 5.
    O’Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992 Dec; 23(12): 1752–60.PubMedCrossRefGoogle Scholar
  6. 6.
    Heiss G, Sharrett AR, Barnes R, et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am J Epidemiol 1991 Aug 1; 134(3): 250–6.PubMedGoogle Scholar
  7. 7.
    Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007 Jan 30; 115(4): 459–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Bedi US, Singh M, Singh PP, et al. Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther 2010 Sep; 15(3): 268–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Bots ML, Evans GW, Riley WA, et al. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations. A point of view. Stroke 2003 Dec; 34(12): 2985–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Crouse III JR, Byington RP, Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 1995 Mar 1; 75(7): 455–9.PubMedCrossRefGoogle Scholar
  11. 11.
    MacMahon S, Sharpe N, Gamble G, et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998 May 12; 97(18): 1784–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Salonen R, Nyyssonen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995 Oct 1; 92(7): 1758–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Crouse III JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007 Mar 28; 297(12): 1344–53.PubMedCrossRefGoogle Scholar
  14. 14.
    Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986 Dec; 74(6): 1399–406.PubMedCrossRefGoogle Scholar
  15. 15.
    Wong M, Edelstein J, Wollman J, et al. Ultrasonic-pathological comparison of the human arterial wall: verification of intima-media thickness. Arterioscler Thromb 1993 Apr; 13(4): 482–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Gamble G, Beaumont B, Smith H, et al. B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. Atherosclerosis 1993 Sep; 102(2): 163–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Wikstrand J. Methodological considerations of ultrasound measurement of carotid artery intima-media thickness and lumen diameter. Clin Physiol Funct Imaging 2007 Nov; 27(6): 341–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Bots ML, de Jong PT, Hofman A, et al. Left, right, near or far wall common carotid intima-media thickness measurements: associations with cardiovascular disease and lower extremity arterial atherosclerosis. J Clin Epidemiol 1997 Jul; 50(7): 801–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Furberg CD, Byington RP, Craven TE. Lessons learned from clinical trials with ultrasound end-points. J Intern Med 1994 Nov; 236(5): 575–80.PubMedCrossRefGoogle Scholar
  20. 20.
    Iglesias del Sol A, Bots ML, Grobbee DE, et al. Carotid intima-media thickness at different sites: relation to incident myocardial infarction. The Rotterdam Study. Eur Heart J 2002 Jun; 23(12): 934–40.CrossRefGoogle Scholar
  21. 21.
    Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987–1993. Am J Epidemiol 1997 Sep 15; 146(6): 483–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Dogan S, Duivenvoorden R, Grobbee ED, et al. Completeness of carotid intima media thickness measurements depends on body composition: the RADIANCE 1 and 2 trials. J Atheroscler Thromb 2010; 17(5): 526–35.PubMedCrossRefGoogle Scholar
  23. 23.
    Bots ML, Evans GW, Riley W, et al. The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics. Control Clin Trials 2003 Dec; 24(6): 752–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Salonen JT, Salonen R. Ultrasound B-mode imaging in observational studies of atherosclerotic progression. Circulation 1993 Mar; 87 (3 Suppl.): II56–65.PubMedGoogle Scholar
  25. 25.
    Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000 Mar 1; 151(5): 478–87.PubMedCrossRefGoogle Scholar
  26. 26.
    O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999 Jan 7; 340(1): 14–22.PubMedCrossRefGoogle Scholar
  27. 27.
    Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998 Feb 15; 128(4): 262–9.PubMedGoogle Scholar
  28. 28.
    Held C, Hjemdahl P, Eriksson SV, et al. Prognostic implications of intima-media thickness and plaques in the carotid and femoral arteries in patients with stable angina pectoris. Eur Heart J 2001 Jan; 22(1): 62–72.PubMedCrossRefGoogle Scholar
  29. 29.
    Kitamura A, Iso H, Imano H, et al. Carotid intima-media thickness and plaque characteristics as a risk factor for stroke in Japanese elderly men. Stroke 2004 Dec; 35(12): 2788–94.PubMedCrossRefGoogle Scholar
  30. 30.
    Rosvall M, Janzon L, Berglund G, et al. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med 2005 May; 257(5): 430–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Rosvall M, Janzon L, Berglund G, et al. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis 2005 Apr; 179(2): 325–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Murakami S, Otsuka K, Hotta N, et al. Common carotid intima-media thickness is predictive of all-cause and cardiovascular mortality in elderly community-dwelling people: Longitudinal Investigation for the Longevity and Aging in Hokkaido County (LILAC) study. Biomed Pharmacother 2005 Oct; 59 Suppl. 1: S49–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Lorenz MW, von KS, Steinmetz H, et al. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006 Jan; 37(1): 87–92.PubMedCrossRefGoogle Scholar
  34. 34.
    Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006 Jul; 37(7): 1933–40.PubMedCrossRefGoogle Scholar
  35. 35.
    Yokoyama H, Katakami N, Yamasaki Y. Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. Stroke 2006 Sep; 37(9): 2420–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001 Dec 4; 135(11): 939–53.PubMedGoogle Scholar
  37. 37.
    Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006 Mar; 27(6): 746–55.PubMedCrossRefGoogle Scholar
  38. 38.
    Angerer P, Stork S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001 Feb; 21(2): 262–8.PubMedCrossRefGoogle Scholar
  39. 39.
    de Groot E, Zwinderman AH, van der Steen AF, et al. Variance components analysis of carotid and femoral intima-media thickness measurements. REGRESS Study Group, Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Ultrasound Med Biol 1998 Jul; 24(6): 825–32.PubMedCrossRefGoogle Scholar
  40. 40.
    Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996 Mar 15; 124(6): 548–56.PubMedGoogle Scholar
  41. 41.
    Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 Oct; 90(4): 1679–87.PubMedCrossRefGoogle Scholar
  42. 42.
    Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996 Dec; 101(6): 627–34.PubMedCrossRefGoogle Scholar
  43. 43.
    Hedblad B, Wikstrand J, Janzon L, et al. Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001 Apr 3; 103(13): 1721–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Beishuizen ED, van de Ree MA, Jukema JW, et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004 Dec; 27(12): 2887–92.PubMedCrossRefGoogle Scholar
  45. 45.
    Shukla A, Sharma MK, Jain A, et al. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients: a controlled randomized trial. Indian Heart J 2005 Nov; 57(6): 675–80.PubMedGoogle Scholar
  46. 46.
    Anderssen SA, Hjelstuen AK, Hjermann I, et al. Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives. Atherosclerosis 2005 Feb; 178(2): 387–97.PubMedCrossRefGoogle Scholar
  47. 47.
    Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004 Dec 7; 110(23): 3512–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007 Apr 19; 356(16): 1620–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 Jul 14; 370(9582): 153–60.PubMedCrossRefGoogle Scholar
  50. 50.
    Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008 Apr 3; 358(14): 1431–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Espeland MA, O’Leary DH, Terry JG, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005 Mar 10; 6(1): 3.PubMedCrossRefGoogle Scholar
  52. 52.
    Smilde TJ, van WS, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001 Feb 24; 357(9256): 577–81.PubMedCrossRefGoogle Scholar
  53. 53.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279(20): 1615–22.PubMedCrossRefGoogle Scholar
  54. 54.
    The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998 Nov 5; 339(19): 1349–57.CrossRefGoogle Scholar
  55. 55.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335(14): 1001–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333(20): 1301–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21; 364(9435): 685–96.PubMedCrossRefGoogle Scholar
  58. 58.
    Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2005–16.PubMedCrossRefGoogle Scholar
  59. 59.
    Deedwania P, Barter P, Carmena R, et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006 Sep 9; 368(9539): 919–28.PubMedCrossRefGoogle Scholar
  60. 60.
    Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) 1994. Atheroscler 2004 Oct Suppl.; 5(3): 81–7.CrossRefGoogle Scholar
  61. 61.
    Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361(9364): 1149–58.PubMedCrossRefGoogle Scholar
  62. 62.
    Serruys PW, de FP, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 Jun 26; 287(24): 3215–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009 Apr 4; 373(9670): 1175–82.PubMedCrossRefGoogle Scholar
  64. 64.
    Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 Nov 22; 357(21): 2109–22.PubMedCrossRefGoogle Scholar
  65. 65.
    Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008 Sep 25; 359(13): 1343–56.PubMedCrossRefGoogle Scholar
  66. 66.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366(9493): 1267–78.PubMedCrossRefGoogle Scholar
  67. 67.
    Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. 2011 Feb;104(2): 109–24.Google Scholar
  68. 68.
    Costanzo P, Perrone-Filardi P, Vassallo E, et al. Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010 Dec 7; 56(24): 2006–20.PubMedCrossRefGoogle Scholar
  69. 69.
    Goldberger ZD, Valle JA, Dandekar VK, et al. Are changes in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A critical review and meta-regression analysis. Am Heart J 2010 Oct; 160(4): 701–14.PubMedCrossRefGoogle Scholar
  70. 70.
    Taylor AJ, Bots ML, Kastelein JJ. Vascular disease: meta-regression of CIMT trials. Data in, garbage out. Nat Rev Cardiol 2011 Mar; 8(3): 128–30.PubMedCrossRefGoogle Scholar
  71. 71.
    Robinson WS. Ecological correlations and the behavior of individuals. Int J Epidemiol 2009 Apr; 38(2): 337–41.PubMedCrossRefGoogle Scholar
  72. 72.
    Lorenz MW, Bickel H, Bots ML, et al. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a meta-analysis project. Am Heart J 2010 May; 159(5): 730–6.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Sanne A. E. Peters
    • 1
  • Hester M. den Ruijter
    • 1
  • Michiel L. Bots
    • 1
  1. 1.Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtCX Utrechtthe Netherlands

Personalised recommendations